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“And it appears to me that one ought also know what
diseases arise in man from the powers and what from the
structures. What do I mean by this? By powers, I mean
intense and strong juices; and by structures, whatever
conformations there are in man.”
—Hippocrates (1)
Offering an insightful hypothesis, Hippocrates correctly
surmised the importance of dynamic circulatory factors in
mediating illness. The search for these elusive “intense and
strong juices” has led us into a fascinating journey of
discovery of inflammatory markers in cardiovascular medi-
cine. More precisely, the significance of systemic and local
inflammation in determining the development and behavior
of atherosclerosis has been the subject of intense scrutiny
(2). Many years ago, Virchow championed the inflamma-
tory theory of atherosclerosis and referred to it as “endarte-
ritis deformans” (3). By this he meant that the atheroma,
initiated by mechanical injury, was a product of inflam-
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mation within the intima and that fibrous thickening
evolved as a reactive consequence by proliferating connective
tissue cells. Contemporary thoughts have continued to
advocate the inflammatory theory of atheroma mediation,
and as Ross reaffirmed, “atherosclerosis is clearly an inflam-
matory disease and does not result simply from the accu-
mulation of lipids” (4). In this issue of the Journal, Hog-
nestad et al. (5) report yet another study that demonstrates
an association between elevated concentrations of plasma
C-reactive protein and allograft atherosclerosis in heart
transplant recipients. Furthermore, these authors deter-
mined that pravastatin 20 mg/day for six weeks reduced
plasma C-reactive protein levels independent of changes in
the lipid profile. These data confirm previous observations
on the association of plasma C-reactive protein, graft
failure, and cardiac allograft vasculopathy (6–8) and, al-
though very preliminary, support the concept that statin
therapy might improve outcomes in cardiac transplantation
by lipid-independent, anti-inflammatory properties.
Cardiac allograft vasculopathy. Cardiac allograft vascu-
lopathy is a unique form of accelerated atherosclerosis of the
allograft and remains the leading cause of late mortality in
patients who survive the first year post transplantation (9).
Although its pathogenesis is not fully elucidated, it seems
that cardiac allograft vasculopathy is associated with an
injury of the coronary vessel endothelium of the trans-
planted heart, initiated by a variety of immunologic factors
(acute rejection, immunosuppressive therapy, human leuko-
cyte antigen mismatches, cytomegalovirus infection) and
propagated by non-immunologic mechanisms (donor age,
lipids, obesity) that result in the development of the char-
acteristic intimal hyperplasia that is the hallmark of this
disease (10–12).
Initial observations demonstrated that only the vessels of
the allograft were involved in this form of accelerated
atherosclerosis, suggesting immunologic mechanisms as the
main underlying factor in the development of this disease
(13). However, despite the successful use of immunosup-
pressive agents and control of rejection, cardiac allograft
vasculopathy still occurs and gives credence to the hypoth-
esis that other nonimmune risk factors acting in concert
with immunologic risk factors are implicated in the devel-
opment of allograft vasculopathy (10–12). Thus, the recog-
nition that rejection-independent events could influence the
development of cardiac allograft vasculopathy became obvi-
ous through investigations that pointed to the role of
ischemia-reperfusion injury surrounding engraftment, the
contribution of advanced donor age, mode of brain death,
aberrances within the microvasculature, and metabolic de-
rangements including hyperlipidemia (10,12,14,15). In-
deed, a recent experimental study demonstrated that allo-
graft vasculopathy could also develop without a cellular
alloimmune response (16).
Inflammation in heart transplantation: immunologic or
non-immunologic? The evidence that inflammation may
be a central event in cardiac allograft vasculopathy and graft
failure, independent of acute allograft rejection, is gaining
acceptance. Several investigations have indicated that early
events that surround engraftment and exemplify inflamma-
tory processes are closely linked with the genesis of cardiac
allograft vasculopathy. In this regard, investigations have
linked the up-regulation of pro-inflammatory cytokines,
markers of diffuse microvascular dysfunction, and procoagu-
lant proteins with graft failure as a result of allograft
vasculopathy (17). Another study by Fyfe et al. (18) dem-
onstrated that serum amyloid-A, another acute-phase pro-
tein, was significantly elevated in cardiac transplant recipi-
ents with allograft vasculopathy. Thus, the consistent
finding of elevated C-reactive protein levels in cardiac
transplantation, along with the demonstration that this is
predictive not only of cardiac allograft vasculopathy but also
of allograft failure, provides another strong step in answer-
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ing the importance of the deleterious effects of low-grade
inflammation in this unique disorder (5–8). Most available
data point to the presence of systemic inflammation without
detectable evidence of immunologically mediated allograft
rejection in cardiac transplantation.
C-reactive protein, atherosclerosis, and cardiac allograft
vasculopathy. C-reactive protein, a sensitive marker of
systemic inflammation, is produced by hepatocytes and
reflects amplification of cytokine activation (19). Recently,
several investigators have shown that C-reactive protein is
an important risk factor for atherosclerosis, coronary artery
disease, and vascular events (2). An increase in plasma levels
of C-reactive protein predicts subsequent cardiovascular
events in healthy men (20) and women (21), patients with
unstable and stable angina (22–24), and those with a history
of myocardial infarction (25).
The relationship between plasma C-reactive protein and
cardiac allograft vasculopathy has come to the forefront in
recent years. First, Eisenberg et al. (7) demonstrated that
plasma levels of C-reactive protein correlated with the
frequency of grade III acute rejection and predicted allograft
failure. In another study by Pethig et al. (6) plasma
C-reactive protein levels were significantly higher in 102
cardiac transplant recipients who had progression of cardiac
allograft vasculopathy by serial coronary angiography. More
recently, Labarrere et al. (8) offered insight into both the
role of C-reactive protein and the underlying mechanism by
which it could contribute to the development of cardiac
allograft vasculopathy. The authors prospectively studied
109 patients in the first three months after cardiac trans-
plantation to investigate the relationship between plasma
C-reactive protein, endomyocardial biopsy findings, inter-
cellular adhesion molecule 1 (ICAM-1) concentrations, and
clinical outcome. During follow-up, the development and
severity of cardiac allograft vasculopathy was significantly
higher in patients with higher C-reactive protein levels. In
addition, the authors demonstrated that C-reactive protein
was closely associated with the expression of endothelial
ICAM-1 and suggested that C-reactive protein could rep-
resent a peripheral marker of allograft inflammation. Fur-
thermore, an investigation of different immunosuppressive
strategies has indicated that C-reactive protein is unaffected
either by the type of immunoprophylaxis employed or by
their effects on allograft rejection (26). The study reported
by Hognestad et al. (5) herein, although observational and
cross-sectional in design, confirms that plasma levels of
C-reactive protein are associated with the development of
cardiac allograft vasculopathy. In addition, in 49 cardiac
transplant recipients, plasma C-reactive protein was mea-
sured at six months after transplantation and compared with
a measurement at late follow-up demonstrating that pa-
tients who developed allograft vasculopathy had a more
significant increase in C-reactive protein than patients who
did not develop allograft vasculopathy.
The crucial question that begs an answer is whether these
findings establish C-reactive protein as a risk factor or
merely a risk marker. The predominant measurement of this
inflammatory marker was performed late after transplanta-
tion (five years), indicating that systemic inflammation
tends to persist throughout the course of transplantation.
Although a retrospective sample at baseline was evaluated in
a smaller subset, this information cannot be construed to
establish the cause-and-effect relationship, because adverse
allograft outcomes 5 years are left unaccounted. Also, the
gold standard used for the diagnosis of cardiac allograft
vasculopathy is imprecise, and it is conceivable that the
diagnostic accuracy of C-reactive protein could have been
further enhanced had intravascular ultrasound been used for
the detection of cardiac allograft vasculopathy (11). There-
fore, these data are best interpreted as indicating that
C-reactive protein is a “marker”—not a “factor”—in arbi-
trating cardiac allograft vasculopathy.
C-reactive protein and statins: a therapeutic target in
heart transplantation? Statins inhibit 3-hydroxy-3-
methylglutaryl–coenzyme A (HMG-CoA) reductase, the
enzyme that catalyzes the conversion of HMG-CoA to
mevalonate; statins also reduce the downstream products of
mevalonate in the cholesterol synthesis pathway. Two of
these downstream products, farnesyl pyrophosphate and
geranylgeranyl pyrophosphate, are the moieties that can
modulate the function of certain essential signaling proteins
that account for anti-inflammatory properties (27). Accu-
mulating more evidence for an anti-inflammatory effect of
statins independent of their lipid-lowering effect, Jialal et al.
(28) have also previously demonstrated that simvastatin,
pravastatin, and atorvastatin decrease high sensitivity
C-reactive protein, indicating that this is probably a class
effect. The demonstration that statin therapy improves
outcomes after heart transplantation independent of lipid
lowering has now been well accepted (29,30). The sugges-
tion that pravastatin reduces C-reactive protein in cardiac
transplantation provides further support that statins exert
their beneficial effects on cardiac allograft vasculopathy by
the reduction of inflammation (5). A recent investigation
conducted for primary and secondary prevention of coronary
artery disease indicated that pravastatin was associated with
a 13% decrease in C-reactive protein levels (31). Yet, the
study by Hognestad et al. (5) suggested a 25% decline in
C-reactive protein levels. Why is this so? It is known that a
synergistic association between statins and cyclosporine
yields incremental anti-inflammatory effects. Thus,
Katznelson et al. (32) have shown that pravastatin and
cyclosporine act synergistically to reduce cytotoxic T lym-
phocyte activity, suggesting that this specific effect is quite
unique to transplant recipients. Despite all these steps in the
right direction, evidence that the C-reactive protein lower-
ing effect influences survival of the allograft is lacking. The
small sample on the effects of pravastatin on C-reactive
protein reported in the current study should be a hypothesis
generating finding to spur further study.
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